| Similar Articles |
|---|
 |
The Motley Fool
December 10, 2007
Brian Lawler |
ImClone in a Giving Mood ImClone Systems and partner Sanofi-Aventis each decide to shell out $60 million to settle a lawsuit over the patents on cancer therapy Erbitux.   |
BusinessWeek
August 21, 2006
Gene G. Marcial |
Repligen May Hit "A Home Run" Shares of Biotech Repligen popped 25%, to 3, on July 31 when a federal judge ruled that its lawsuit seeking royalties from ImClone Systems could proceed. |
The Motley Fool
October 2, 2008
Brian Orelli |
Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal? |
The Motley Fool
April 27, 2004
Alyce Lomax |
Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux. |
The Motley Fool
August 1, 2007
Brian Lawler |
ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth. |
The Motley Fool
April 28, 2008
Brian Lawler |
ImClone on the Upswing The pharmaceutical's latest results show continuing improvement. |
The Motley Fool
April 29, 2004
Bill Mann |
Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses. |
The Motley Fool
April 5, 2007
Brian Lawler |
ImClone Steps to the Front ImClone announces a successful clinical trial for the cancer drug Erbitux. Investors, take note. |
The Motley Fool
September 11, 2008
Brian Lawler |
ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after. |
The Motley Fool
April 20, 2004
Charly Travers |
Great Googly Moogly, ImClone The biopharmaceutical company's stock is going crazy again. |
The Motley Fool
April 17, 2007
Brian Lawler |
ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note. |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
BusinessWeek
March 8, 2004
Arnst & Ewing |
The Odyssey Of A Cancer Drug How ImClone overcame scandal and FDA objections to get Erbitux to market |
The Motley Fool
January 29, 2007
Brian Lawler |
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note. |
The Motley Fool
April 27, 2007
Brian Lawler |
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note. |
The Motley Fool
July 20, 2006
Brian Lawler |
No Surprises From ImClone ImClone's lead product experienced strong revenue growth in the second quarter. But biotech investing is fraught with risk. Investors, take note. |
The Motley Fool
October 30, 2007
Brian Lawler |
ImClone Onward Global sales, and excitement about new label expansions for lead drug Erbitux, lift ImClone's third-quarter financial results. |
The Motley Fool
July 16, 2007
Brian Lawler |
Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note. |
The Motley Fool
June 4, 2008
Brian Lawler |
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares. |
| Knowledge@Wharton |
Bristol-Myers Squibb Illustrates Woes of Ailing Pharmaceutical Industry The once-mighty pharmaceutical industry, for years the nation's most profitable, has begun to show some cracks. But no major U.S. drug maker seems to be facing more problems than Bristol-Myers Squibb. |
The Motley Fool
December 16, 2011
Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. |
The Motley Fool
August 26, 2009
Brian Orelli |
Small Change, Big Impact? A small difference in wording could have a huge effect on sales of Bristol-Myers Squibb's Orencia. |
The Motley Fool
September 13, 2007
Brian Lawler |
ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux. |
The Motley Fool
September 1, 2004
Bill Mann |
Triumph of Hope Over Reason A frighteningly expensive drug of marginal efficacy begets triple-digit multiples? Bring on the miracles. Standard & Poor's reiterated its "buy" rating of ImClone. |
The Motley Fool
February 12, 2004
Bill Mann |
ImClone's Mysterious Plunge Investors flee the stock the instant before it receives great news. Oops. |
The Motley Fool
August 30, 2007
Brian Lawler |
ImClone's Healthy Pipeline With three new molecules in phase 2 testing and another two in phase 1 testing by the end of the year, ImClone may not be completely reliant on Erbitux for its fortunes in the coming years. |
The Motley Fool
September 22, 2008
Brian Lawler |
Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems. |
The Motley Fool
June 12, 2007
Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label. |
